Nexviadyme, the new Enzyme Replacement Therapy (ERT) for Pompe, developed by Sanofi, has been recommended by NICE, the National Institute for Health and Care Excellence. The full recommendation and guidance are now posted on the NICE website.
It is expected that once the commercial arrangement is in place, Nexviadyme will be available for patients through the NHS specialist centres for LSDs. That is expected to be within thirty days in England and two months in Wales.
The new treatment is recommended for all patients, both infantile-onset Pompe disease (IOPD) and late-onset (LOPD).
Please contact Pompe Support Network - hello@Pompe.uk - if you require any further advice or support.